Form PTO-1390 (REV 10-2000) IMERCE PATENT AND TRADEMARK OFFICE ATTORNEY'S DOCKET NUMBER 1085.0050000/RWE TRANSMITTAL LETTER TO THE UNITED STATES U.S. APPLICATION NO. (IF KNOWN, SEE 3PC) DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 INTERNATIONAL FILING DATE INTERNATIONAL APPLICATION NO PRIORITY DATE CLAIMED PCT/GB99/01388 05 May 1999 05 May 1998 TITLE OF INVENTION MELANOCORTIN 1 RECEPTOR SELECTIVE COMPOUNDS APPLICANT(S) FOR DO/EO/US SZARDENINGS, Michael; MUCENIECE, Ruta; MUTULE, Ilze; MUTULIS, Felikss; WIKBERG, Jarl Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The US has been elected by the expiration of 19 months from the priority date (PCT Article 31). A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). Amendments to the claims of the International application under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 372(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11. to 16. below concern other document(s) or information included: An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98. An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. A substitute specification. A change of power of attorney and/or address letter. Other items or information: Copy of published International Application No. PCT/GB99/01388, including 62 pages of specification prior to the claims; 13 pages claims (claims 1-64); 6 sheets drawings (Figures 1-6); 8 pages Sequence Listing; 2 pages International Search Report; and 1 page abstract. Copy of the International Preliminary Examination Report for PCT/GB99/01388, including annexes. Claim For Priority Under 35 U.S.C. § 119(a)-(d) In Utility Application, with certified copy of Swedish Application No. 9801571-2, filed May 5, 1998. Authorization To Treat A Reply As Incorporating An Extension Of Time Under 37 C.F.R. § 1.136(a)(3) (in duplicate).

	εε		•	529 F	lea l	PCT/PTC 0	6 NOV 2000		
	U.37APPLIC (10 Octo, fragen, set 3/ c.f. R 1.507 INTERNATIONAL APPLICATION NO. PCT/GB99/01388					ATTORNEYS DOCKET NUMBER 1085.00500005/RWE			
Ī	17. X The following fees are submitted:					CALCULATIONS	PTO USE ONLY		
Basic National Fee (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO					00.00		•		
	International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO								
	international search	International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO							
	but all claims did	International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4)							
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)									
		ENTER AI	PPROPRIATE BASIC	FEE AMOUNT	=	\$ 860.00			
		for furnishing the oath oned priority date (37 CF)		□ 20 🖾 30 month	S	\$ 130.00			
ſ	Claims	Number Filed	Number Extra	Rate					
	Total Claims	- 20 =		X \$18.00	\$	-0-			
	Independent Claims	-3 =		X \$80.00	\$	-0-			
	Multiple dependent cl	ltiple dependent claim(s) (if applicable) + \$270.00				\$ -0-			
			TOTAL OF ABOVE CALCULATIONS =			990.00			
	Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	990.00	1 11 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		
ļ	·-··			SUBTOTAL =	\$	990.00			
ļ	J	00 for furnishing the Englis date (37 CFR 1.492(f)).	translation later than 20 30 months from the		\$	-0-			
ļ	· · · · · · · · · · · · · · · · · · ·	·	TOTAL NATIONAL FEE =			990.00	· · · · · · · · · · · · · · · · · · ·		
		ng the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				-0-	· • • • • • • • • • • • • • • • • • • •		
	TOTAL FEES ENCLOSED =					.990.00			
						Amount to be refunded:	\$		
						charged:	\$		
	 a. ☑ A check in the amount of \$990.00 to cover the above fees is enclosed. b. ☐ Please charge my Deposit Account No in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed. c. ☐ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit 								
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to D Account No. 19-0036. A duplicate copy of this sheet is enclosed. NOTE: Where an appropriate time limit Under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a must be filed and granted to restore the application to pending status.									
	SEND ALL CORRESPONDENCE TO:				ber	tw. Somere			
		ERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.				. W. Co	DATE		
		00 New York Avenue, NW, Suite 600 shington, D.C. 20005-3934				bert W. Esmond			
		3					2,893		
1	REGIST					RATION NUMBER			

SKGF Rev. 10/2/00 mac

Form PTO-1390 (REV 12-29-99) page 2 of 2

P:\USERS\DENISEB\1085\005appfrm

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Szardenings et al.

Appl. No. (U.S. National Phase of

PCT/GB99/01388; U.S. Appl.

No. (to be assigned))

Int'l Filing Date: May 5, 1999

For: Melanocortin 1 Receptor Selective

Compounds

Art Unit: (To be assigned)

Examiner: (To be assigned)

Atty. Docket: 1085.0050000/RWE

Authorization To Treat A Reply As Incorporating An Extension Of Time Under 37 C.F.R. § 1.136(a)(3)

Commissioner for Patents **Box PCT** Washington, D.C. 20231

Sir:

The U.S. Patent and Trademark Office is hereby authorized to treat any concurrent or future reply that requires a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. The U.S. Patent and Trademark Office is hereby authorized to charge all required extension of time fees to our Deposit Account No. 19-0036, if such fees are not otherwise provided for in such reply. A duplicate copy of this authorization is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Robert W. Esmond Attorney for Applicants Registration No. 32,893

Date: November 6, 2000

1100 New York Avenue, N.W. Suite 600 Washington, D.C. 20005-3934 (202) 371-2600